Current status of intravascular stents as delivery devices to prevent restenosis

Vascular and Endovascular Surgery

Volumn 37, Issue 4, 2003, Pages 231-237

  Pearce, Benjamin J ^b   McKinsey, James F ^a   Bandyk, Dennis ^b  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIPROLIFERATIVE AGENT; DRUG; PACLITAXEL; RAPAMYCIN; TRANILAST; UNCLASSIFIED DRUG;

BRACHYTHERAPY; CLINICAL TRIAL; CORONARY ARTERY DILATATION; CORONARY STENT; DIARRHEA; HUMAN; HYPERPLASIA; INFLAMMATION; INTIMA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; REVIEW; SEIZURE; STENT; THROMBOCYTOPENIA; TREMOR; VERTIGO;

EID: 0042266458     PISSN: 15385744     EISSN: None     Source Type: Journal    
DOI: 10.1177/153857440303700401     Document Type: Review

References (44)

1. Gruntzig AR, Senning A, Siegenthaler WE: Nonoperative dilatation of coronary-artery stenosis: Percutaneous transluminal coronary angioplasty. N Engl J Med 301:61-68, 1979.
2. Gruentzig AR, King SB III, Schlumpf M, et al: Long-term follow-up after percutaneous transluminal coronary angioplasty. The early Zurich experience. N Engl J Med 316:1127-1132, 1987.
3. Nobuyoshi M, Kimura T, Nosaka H, et al: Restenosis after successful percutaneous transluminal coronary angioplasty: Serial angiographic follow-up of 229 patients. J Am Coll Cardiol 12:616-623, 1988.
4. Holmes DR Jr, Van Raden MJ, Reeder GS, et al: Return to work after coronary angioplasty: A report from the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry Design of comparative clinical studies of percutaneous transluminal coronary angioplasty using estimates from the Coronary Artery Surgery Study. Am J Cardiol 53:48C-51C, 1984.
5. Fischman DL, Leon MB, Baim DS, et al: A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 331:496-501, 1994.
6. Al Suwaidi J, Berger PB, Holmes DR Jr: Coronary artery stents. JAMA 284:1828-1836, 2000.
7. Serruys PW, de Jaegere P, Kiemeneij F, et al: A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 331:489-495, 1994.
8. Cutlip DE, Chauhan MS, Baim DS, et al: Clinical restenosis after coronary stenting: Perspectives from multicenter clinical trials. J Am Coll Cardiol 40:2082-2089, 2002.
9. Isles CG, Robertson S, Hill D: Management of renovascular disease: A review of renal artery stenting in ten studies. QJM 92:159-167, 1999.
10. Kandarpa K, Becker GJ, Hunink MG, et al: Transcatheter interventions for the treatment of peripheral atherosclerotic lesions: Part I. J Vasc Interv Radiol 12:683-695, 2001.
11. Lee ES, Steenson CC, Trimble KE, et al: Comparing patency rates between external iliac and common iliac artery stents. J Vasc Surg 31:889-894, 2000.
12. Siskin GP, Englander M, Roddy S, et al: Results of iliac artery stent placement in patients younger than 50 years of age. J Vasc Interv Radiol 13:785-790, 2002.
13. Murphy TP, Khwaja AA, Webb MS: Aortoiliac stent placement in patients treated for intermittent claudication. J Vasc Interv Radiol 9:421-428, 1998.
14. Oberhoff M, Herdeg C, Baumbach A, et al: Stent-based antirestenotic coatings (sirolimus/paclitaxel). Cathet Cardiovasc Interv 55:404-408, 2002.
15. Kandzari DE, Tcheng JE, Zidar JP: Coronary artery stents: Evaluating new designs for contemporary percutaneous intervention. Cathet Cardiovasc Interv 56:562-576, 2002.
16. Farb A, Sangiorgi G, Carter AJ, et al: Pathology of acute and chronic coronary stenting in humans. Circulation 99:44-52, 1999.
17. Barth KH, Virmani R, Froelich J, et al: Paired comparison of vascular wall reactions to Palmaz stents, Strecker tantalum stents, and Wallstents in canine iliac and femoral arteries. Circulation 93:2161-2169, 1996.
18. Schwartz RS, Huber KC, Murphy JG, et al: Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol 19:267-274, 1992.
19. Schillinger M, Exner M, Mlekusch W, et al: Balloon angioplasty and stent implantation induce a vascular inflammatory reaction. J Endovasc Ther 9:59-66, 2002.
20. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, et al: Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 21:1152-1158, 2000.
21. Schillinger M, Haumer M, Schlerka G, et al: Restenosis after percutaneous transluminal angioplasty in the femoropopliteal segment: The role of inflammation. J Endovasc Ther 8:477-483, 2001.
22. Schillinger M, Exner M, Mlekusch W, et al: Inflammatory response to stent implantation: Differences in femoropopliteal, iliac, and carotid arteries. Radiology 224:529-535, 2002.
23. Gallino A, Mahler F, Probst P, et al: Percutaneous transluminal angioplasty of the arteries of the lower limbs: A 5-year follow-up. Circulation 70:619-623, 1984.
24. Krepel VM, van Andel GJ, van Erp WF, et al: Percutaneous transluminal angioplasty of the femoropopliteal artery: Initial and long-term results. Radiology 156:325-328, 1985.
25. Matsi PJ, Manninen HI, Vanninen RL, et al: Femoropopliteal angioplasty in patients with claudication: Primary and secondary patency in 140 limbs with 1-3-year follow-up. Radiology 191:727-733, 1994.
26. Fischer-Dzoga K, Dimitrievich GS, Griem ML: Radiosensitivity of vascular tissue. II. Differential radiosensitivity of aortic cells in vitro. Radiat Res 99:536-546, 1984.
27. Hansrani M, Overbeck K, Smout J, et al: Intravascular brachytherapy: A systematic review of its role in reducing restenosis after endovascular treatment in peripheral arterial disease. Eur J Vasc Endovasc Surg 24:377-382, 2002.
28. Sidawy AN, Weiswasser JM, Waksman R: Peripheral vascular brachytherapy. J Vasc Surg 35:1041-1047, 2002.
29. Coen VL, Knook AH, Wardeh AJ, et al: Endovascular brachytherapy in coronary arteries: The Rotterdam experience. Cardiovasc Radiat Med 2:42-50, 2000.
30. Teirstein PS, Massullo V, Jani S, et al: Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 336:1697-1703, 1997.
31. Teirstein PS, Massullo V, Jani S, et al: Three-year clinical and angiographic follow-up after intracoronary radiation: Results of a randomized clinical trial. Circulation 101:360-365, 2000.
32. Liermann D, Kirchner J, Bauernsachs R, et al: Brachytherapy with iridium-192 HDR to prevent restenosis in peripheral arteries. An update. Herz 23:394-400, 1998.
33. Minar E, Pokrajac B, Maca T, et al: Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: Results of a prospective randomized study. Circulation 102:2694-2699, 2000.
34. Pokrajac B, Minar E, Kirisits C, et al: Present status of endovascular brachytherapy in peripheral arteries. Herz 27:56-61, 2002.
35. Sapirstein W, Zuckerman B, Dillard J: FDA approval of coronary-artery brachytherapy. N Engl J Med 344:297-299, 2001.
36. Holmes DR Jr, Savage M, LaBlanche JM, et al: Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 106:1243-1250, 2002.
37. Edelman ER, Adams DH, Karnovsky MJ: Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc Natl Acad Sci USA 87:3773-3777, 1990.
38. Klugherz BD, Llanos G, Lieuallen W, et al: Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis 13:183-188, 2002.
39. Morice MC, Serruys PW, Sousa JE, et al: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773-1780, 2002.
40. Degertekin M, Regar E, Tanabe K, et al: Sirolimus eluting stent in the treatment of atherosclerosis coronary artery disease. Minerva Cardioangiol 50:405-418, 2002.
41. Rowinsky EK, Donehower RC: Paclitaxel (taxol). N Engl J Med 332:1004-1014, 1995.
42. Farb A, Heller PF, Shroff S, et al: Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104:473-479, 2001.
43. Grube E, Silber S, Hauptmann KE, et al: TAXUS I: Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107:38-42, 2003.
44. Liistro F, Stankovic G, Di Mario C, et al: First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: Immediate and long-term clinical and angiographic outcome. Circulation 105:1883-1886, 2002.